Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07403721 · ClinicalTrials.gov registry record · Phase 1
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
A Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR), sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 464
- Enrollment target
- 2
- Study locations
NCT07403721 is a Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) that is actively recruiting participants, run by Amgen. The registered enrollment target is 464 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT07403721, a Phase 1 study of Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR), is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 464 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
Conditions Studied
Interventions
- DRUG AMG 436
Study Locations (2)
Texas
- Next Oncology - Dallas - Irving
Aichi-ken
- Aichi Cancer Center - Nagoya
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2028-06-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07403721
The ClinicalTrials.gov registry entry for NCT07403721 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) appearing as the primary indexed condition, and to 1 intervention - of which AMG 436 is the first listed.
NCT07403721 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Aichi-ken.
Frequently Asked Questions
What is clinical trial NCT07403721 about?
NCT07403721 is a clinical study titled "AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors". The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.
What is the current status of trial NCT07403721?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 464 participants. The study started on 2026-03-23. Estimated completion is 2028-06-28.
What conditions does trial NCT07403721 study?
This clinical trial studies the following conditions: Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR).
What interventions are being tested in trial NCT07403721?
The interventions under investigation include: AMG 436 (DRUG).
Who is sponsoring clinical trial NCT07403721?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07403721 being conducted?
This trial has 2 study locations across Texas, Aichi-ken. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.